Q4B Annex 6 Uniformity of Dosage Units General ChapterQ4B附录6 统一剂量单位 常规篇
VIP免费
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL
REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED TRIPARTITE GUIDELINE
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
TEXTS FOR USE IN THE ICH REGIONS
ON
UNIFORMITY OF DOSAGE UNITS GENERAL CHAPTER
Q4B ANNEX 6
Current
Step 4
version
dated 13 November 2013
This Guideline has been developed by the appropriate ICH Expert Working Group
and has been subject to consultation by the regulatory parties, in accordance with the
ICH Process. At Step 4 of the Process the final draft is recommended for adoption to
the regulatory bodies of the European Union, Japan and USA.
Q4B Annex 6
Document History
Code
History
Date
Q4B Annex 6
Approval by the Steering Committee under
Step 2
and release
for public consultation.
13 November
2008
Q4B Annex
6(R1)
Integration into
Step 2
of the Health Canada
Interchangeability Statement under Section 4.5 after
approval by the Steering Committee.
27 September
2010
Current
Step 4
version
Q4B Annex 6
Approval by the Steering Committee under
Step 4
and
recommendation for adoption to the three ICH regulatory
bodies. The R was removed from the name of the document as
this is the first version of the Annex 6
Step 4.
13 November
2013
i
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
TEXTS FOR USE IN THE ICH REGIONS
ON
UNIFORMITY OF DOSAGE UNITS GENERAL CHAPTER
Q4B ANNEX 6
ICH Harmonised Tripartite Guideline
Having reached
Step 4
of the ICH Process at the ICH Steering Committee meeting on 13
November 2013, this guideline is recommended for adoption
to the three regulatory parties to ICH.
TABLE OF CONTENTS
1. INTRODUCTION...................................................................................................... 1
2. Q4B OUTCOME ........................................................................................................ 1
2.1 Analytical Procedures .................................................................................................... 1
2.2 Acceptance Criteria ....................................................................................................... 1
3. TIMING OF ANNEX IMPLEMENTATION .............................................................. 1
4. CONSIDERATIONS FOR IMPLEMENTATION ...................................................... 1
4.1 General Consideration ................................................................................................... 1
4.2 FDA Consideration ........................................................................................................ 1
4.3 EU Consideration .......................................................................................................... 2
4.4 MHLW Consideration .................................................................................................... 2
4.5 Health Canada Consideration ....................................................................................... 2
5. REFERENCES USED FOR THE Q4B EVALUATION ............................................. 2
标签: #附录
摘要:
展开>>
收起<<
INTERNATIONALCONFERENCEONHARMONISATIONOFTECHNICALREQUIREMENTSFORREGISTRATIONOFPHARMACEUTICALSFORHUMANUSEICHHARMONISEDTRIPARTITEGUIDELINEEVALUATIONANDRECOMMENDATIONOFPHARMACOPOEIALTEXTSFORUSEINTHEICHREGIONSONUNIFORMITYOFDOSAGEUNITSGENERALCHAPTERQ4BANNEX6CurrentStep4versiondated13November2013ThisGuide...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
ISO17025:2017一整套程序文件(实验室认可服务)VIP免费
2024-06-05 113 -
医疗器械工作程序文件VIP免费
2024-12-10 158 -
确认与验证管理规程VIP免费
2025-04-21 51 -
有害物质管理程序(含表格)VIP免费
2025-05-04 70 -
医疗器械上市后临床跟踪控制程序VIP免费
2025-10-27 46 -
供应商质量管理程序VIP免费
2025-11-07 64 -
DC2-07001 设备设施控制程序VIP免费
2026-03-21 10 -
DC2-07001 设备设施控制程序1VIP免费
2026-03-21 8 -
DC2-08001 与顾客有关的过程控制程序VIP免费
2026-03-21 6 -
DC2-09001 环境因素识别、评价与控制程序VIP免费
2026-03-21 12
作者:冒牌货
分类:专业资料
价格:50质量币
属性:6 页
大小:62.85KB
格式:PDF
时间:2025-12-24

